posted
not likely,thats right around support and my order would cover it there I believe....might be moving it up to .059 though if its still locked up around 2pm
posted
im not bashing this stock, but i would wait to see where this heads before buying right now.
Posts: 1088 | From: Dallas, Texas | Registered: Feb 2006
| IP: Logged |
posted
Whoew..i knew it should have got in this 2 weeks ago was on my watch list..bahh too late to chase i think a good entry point for this is around in the low .052-.055.But good luck to all of you who got in early..I'll be back:)
Posts: 158 | From: Phila,PA | Registered: Mar 2006
| IP: Logged |
The Catholic Church in Korea has decided to donate money for adult stem cell research. The move comes amid strong Vatican opposition to embryonic stem cell research and is reflects support for research into an alternative. The Church has been among the most vocal opponents of embryonic stem cell research based on the belief that embryos are human beings. In Korea, a country leading that field of science, the Catholic Church is donating millions of dollars to aid research involving adult stem cells in the hope of reducing the increasing reliance on embryonic stem cells to treat hard-to-cure diseases.
"The research harms the integrity of life, and that's why we cannot accept the use of embryos," the church said. It wants to fund research on adult stem cells derived from bone marrow or umbilical cords that would otherwise be discarded after a baby is born. They say this is more practical and does not cause ethical controversy.
Stem Cell Therapies In The Future In Stem Cell Therapies Today, we saw how stem cells are being used to treat diseases such as leukemia. Stem cell transplant procedures also show promise for treating neurological disorders such as Parkinson's disease.
What does the future hold for stem cell therapies?
Researchers and physicians are working to design stem cell therapies that
Are more effective, and Reduce the invasiveness and the risk to patients Today's stem cell therapies usually rely on cells that are donated by another person. This raises the possibility of donor cell rejection by the patient's immune system. In the future, it may be possible for a person to use a sample of his or her own stem cells to regenerate tissue, which would reduce or even eliminate the danger of rejection. How might this be done? Some possibilities include:
Collecting healthy adult stem cells from a patient and manipulating them in the laboratory to create new tissue. The tissue would be re-transplanted back into the patient's body, where it would work to restore a lost function. Therapeutic cloning, as described in Creating Stem Cells for Research, might enable the creation of embryonic stem cells that are genetically identical to the patient. One less invasive way to achieve this goal would be to manipulate existing stem cells within the body to perform therapeutic tasks. For example, scientists might design a drug that would direct a certain type of stem cell to restore a lost function inside the patient's body. This approach would eliminate the need for invasive surgical procedures to harvest and transplant stem cells. On the surface, the possibilities for stem cell therapy seem limitless. Couldn't we use stem cell technologies to replace any diseased or damaged tissue in the body? To answer this question, researchers must figure out the true potential and limitations of stem cells. Some questions currently being addressed include:
How long will a stem cell therapy last?
The reason we age is because our cells do. If adult stem cells are used in therapies, will the tissues created from those cells age and malfunction more quickly? Scientists don't yet know how long different stem cell treatments might last.
this is whats happening in Korea.....don't you think the stem cell banking is going to go crazy here to so people will have a resource of their on stem cells for any problems in the future?
Applications flood stem cell bank
A new global stem cell centre in South Korea says it has been inundated with applications from patients willing to take part in research at the institute. Officials said about 3,500 patients volunteered on Tuesday, the centre's first day accepting applications.
The project is being led by cloning expert Dr Woo Suk Hwang, who has pioneered the development of stem cells tailored to individual patients.
Critics say using human embryos in research is unnecessary and unethical.
But proponents argue that stem cells taken from embryos offer the best hope of new treatments for a range of diseases and injuries.
By the end of Tuesday, some 3,500 applications had been received via the internet, telephone, fax and in person, said Lim Jong-pil, an official at the research centre at Seoul National University Hospital.
The centre did not receive any applications from foreign nationals, even though they were eligible, Mr Lim said.
It has not set a deadline for applications, neither has it decided when trials will begin.
"Sometimes a good idea comes to you when you are not looking for it. Through an improbable combination of coincidence, naiveté and lucky mistakes ..." Kary B. Mullis (The Unusual Origin of the Polymerase Chain Reaction, Sci. Amer., April 1990, p. 445).
He testified for the defence (against PCR) at the trial of OJ Simpson.
He also believes that HIV does not cause AIDS.
He's the head of the CLBE scientific advisory board.
question---I read in a new article recently that the current value of the stem cell industry in the year 2005 is about 500 million dollars. They estimate that the industry by the year 2010 only five years from now will be worth 30 Billion dollars a year... With a 60 times the revenue in 2010
Chart Indicators Ind. short Inter Long EMA VBu VBu VBu MACD VBu VBu VBu RSI Bu TDD Bu Fibs VBu Bu VBe Highs Be VBe VBe Lows VBu Be Be Trends N Be Bu Stoch. VBu VBu=Very Bullish, Bu=Bullish N=Neutral Be=Bearish, VBe=Very Bearish
posted
I think the quarterly report is going to have the biggest impact on the PPS and that should be coming out anywhere between the end of July or mid August....they clearly stated they expect to be profitable in 2006 and with the parent and all the sub-divisions showing successful operations I think this investment will pay off in a major way for anyone holding long.I still think this will be worth $2 to $4 within the next 18 to 24 months and I am usually very conservative at these estimates.
MoleculA was founded in 1993 to provide high quality antisense oligonucleotides to researchers worldwide. As the company has grown it has diversified and expanded into other market sectors to meet the critical needs of basic researchers and specialized biopharmaceutical manufacturers.
Starting with the introduction of a line of neuropeptides under the brand name of Princeton Peptides in 1994, MoleculA met the needs of the gene function market by providing high purity agonists and antagonists that were bulk packaged to provide the best value to customers, as well as custom oligo and peptide services.
In 1999 MoleculA began expending tremendous effort to develop new products like Maxfect™, Genfect™ and iFECT™ transfection reagents as well as The Inducer™ - a novel IPTG replacement for increased soluble protein production.
MoleculA, now a subsidiary of CalbaTech, is actively expanding its product range in siRNA. This builds upon its well-established reputation as a designer and supplier of active antisense oligonucleotides. MoleculA focuses on gene function solutions using RNAi technology.
MoleculA also develops and sells numerous research reagents for cell transfection, DNA and RNA purification, protein expression, microarray analysis and other innovative and fundamental products.
MoleculA looks forward to serving our customers in any possible way. If there is something that you are having a difficult time sourcing please contact us. We have many industry connections and may be able to assist you with varying options and better pricing.
We encourage any questions or comments you may have.
posted
I think maybe the left coast boys woke up and maybe getting ready to give the share holders a little message...LOL..They are a Cali company so I guess we have to play on their time table.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
But I only have 30k shares ![[Frown]](frown.gif)
